



# VI Best of ASTRO

## PROGRAMA



**12 y 13 de Mayo de 2022**  
**Hotel Scala - Bernardo de Irigoyen 740**  
**Buenos Aires - Argentina**



SCIENCE OF TODAY  
HOPE FOR TOMORROW

**Argentina**

**Este evento se realiza con licencia de American Society of Radiation Oncology “ASTRO” con el objetivo de difundir los trabajos con mejor puntuación del ASTRO Annual Meeting del año 2021, October 24 – 27, Chicago, USA**

## **Comisión Directiva 2020 - 2022**



### **Presidente**

Dr. Gustavo Ferraris

### **Vicepresidente**

Dra. Verónica Vázquez Balcarce

### **Secretario General**

Dra. María Fernanda Díaz Vázquez

### **Secretario de Actas**

Dr. José Máximo Barros

### **Prosecretario**

Dra. Claudia Benavento

### **Tesorero**

Dra. Carmen Castro

### **Protesorero**

Dr. Oscar Gómez Orrego

### **Vocales Titulares**

Dr. Jorge Palazzo

Dra. Luisa Rafailovici

Dra. Mabel Sardi

Dr. Carlos Cardello

Dra. Patricia Bruno

Dra. Carolina Chacón

### **Vocales Suplentes**

Dr. Lucas Causa

Dr. Marcelo Andrade Irusta

Dra. María Cecilia Coll

Dr. Federico Díaz

Dra. María José Girola

Dra. Claudia De Angelis

Dr. Carlos Donoso

### **Órgano de fiscalización**

#### **Revisores de Cuentas Titulares**

Dr. Javier Otero

Dr. Mauro Mattio

Dra. Vanesa Krakobsky

#### **Revisor de Cuentas Suplente**

Dr. Ignacio Sisamón

Dra. Luz Font

#### **Comité de Ética**

Dra. Ana Mabel Martínez

Dra. Estela Broda

Dr. Ricardo Alva

Dr. Hugo Donato

#### **Comité Científico**

Dra. Luisa Rafailovici

Dra. María Luisa Filomía

Dra. Mabel Sardi

## *Información General*

### **Secretaría SATRO:**

**Sra. Rosario Val**

**Cel / Whatsapp:** +54911 6369-6348

**e-mail:** [satro@fibertel.com.ar](mailto:satro@fibertel.com.ar) // [xina\\_arg@hotmail.com](mailto:xina_arg@hotmail.com)

**Sitio web:** [www.satro-radioterapia.com.ar](http://www.satro-radioterapia.com.ar)

**Facebook:** Sociedad Argentina de Terapia Radiante Oncologic

**Instagram:** socterapiaradiante

**YouTube:** Satro Radioterapia

### **Secretaría Evento:**

**IV Eventos – Lic. Inés Vuoto**

**Cel / Whatsapp:** +54911 5035-0701

**e-mail:** [ines@iveventos.com](mailto:ines@iveventos.com)

# Invitados Extranjeros




**Dr. Felipe Couñago**  
**Madrid, España**  
Oncología Radioterápica  
Hospital Universitario  
Quirónsalud Madrid



**Dra. Ana Díaz Gavela**  
**Madrid, España**  
Oncología Radioterápica  
Hospital Universitario  
Quirónsalud Madrid



**Dr. Mauricio Luongo**  
**Montevideo, Uruguay**  
Oncólogo Radioterapeuta  
Centro de Oncología y  
Radioterapia del Litoral  
Director Técnico de la  
Clínica COR



**Dra. Marina Peña Huertas**  
**Madrid, España**  
Oncología Radioterápica  
Hospital Universitario  
Quirónsalud Madrid



**Dr. Aldo Quarneti**  
**Montevideo, Uruguay**  
Profesor Titular de la  
Cátedra de Oncología  
Radioterápica, Facultad  
de Medicina de la  
Universidad del Uruguay



**Dra. Carmen Rubio**  
**Madrid, España**  
Jefe de Servicio de  
Oncología Radioterápica de  
HM Hospitales



**Dr. Gustavo Sarria**  
**Lima, Perú**  
Sub Jefe Institucional  
Instituto Nacional de  
Enfermedades Neoplásicas

# Agradecemos la Colaboración de las Sigüientes Empresas

## SPONSORS DIAMANTE

**varian**



Distribuidor Autorizado



## SPONSORS PLATINO

AstraZeneca 



Distribuidor exclusivo



## SPONSORS ORO

**INIAAP**



# Jueves 12 de Mayo

**08:00 – 15:30 hs. Acreditación**

**09:00 – 10:15 hs. Módulo 1: Cáncer de Cabeza y Cuello**

**09:00 – 09:05 hs. Presidente: Dr. Jorge Palazzo, Vidt Centro Médico, Tucumán**

**Coordinador: Dr. Marcos David Pereira,  
Instituto de Oncología Ángel Roffo, Buenos Aires**

**Disertantes:**

**09:05 – 09:15 hs. Dr. Carlos Alberto Cardiello, Vidt Centro Médico, Buenos Aires**

**Abstract 68: Long-term Results for MC1273, A Phase II Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)**

**Abstract 70: Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis Head and Neck Cancer**

**09:15 – 09:25 hs. Dra. Cecilia Coll, Instituto Privado de Radioterapia Cuyo, Mendoza**

**Abstract 74: Final Report of NRG Oncology RTOG 0022: A Phase I/II Study of Conformal and Intensity Modulated Radiation for Oropharyngeal Cancer**

**Abstract 75: Surgical Drain Fluid as a Novel Liquid Biopsy Analyte to Measure Postoperative Minimal Residual Disease in HPV+ Oropharyngeal Cancer**

**09:25 – 09:35 hs. Dr. Diego Fernández, Centro de Radioterapia Dean Funes, Córdoba**

**Abstract 71: Development of a hypoxia-immune prognostic classifier for head-and-neck cancer patients undergoing radiotherapy – results from a prospective imaging trial**

**Abstract 72: A Randomized Controlled Trial of Reirradiation Using Diffusion-weighted MRI Guided Dose-painting versus CT-based Radiotherapy for Locally Recurrent T3 to T4 Nasopharyngeal Carcinoma**

**09:35 – 09:45 hs. Dr. Emilio Astiz, CEDITRA, Buenos Aires**

**Abstract 69: Randomized Phase III, Double-Blind, Placebo-Controlled Study of Prophylactic Gabapentin for the Reduction of Radiation Therapy-Induced Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma**

**Abstract 77: Association of Pathologic Nodal Metastasis Count with Oncologic Outcomes in Head and Neck Cancer: A Secondary Analysis of RTOG 9501, RTOG 0234, and EORTC 22931**

**09:45 – 10:15 hs. Mesa de Discusión:**

**Coordinador: Dr. David Pereira (RT)**

**Panelistas: Dr. Jorge Palazzo (RT), Dr. Carlos Cardiello (RT), Dra. Cecilia Coll (RT),  
Dr. Diego Fernández (RT), Dr. Emilio Astiz (RT)  
Dr. Federico Cayol, (Oncología Clínica), Hospital Italiano, Buenos Aires  
Dr. Alejandro Yanzon (Cirugía), Hospital Italiano, Buenos Aires**

# *Jueves 12 de Mayo*

*10:15 – 10:45 hs. - Inauguración VI Best of ASTRO*

**Dr. Gustavo Ferraris, Presidente SATRO**

**Prof. Dr. Miguel Galmés,  
Presidente Asociación Médica Argentina**

*- Reconocimiento SATRO a la trayectoria*

*10:45 – 11:20 hs. Intervalo Café*

*11:20 – 11:50 hs. Sesión Presidencial*

*12:00 – 12:30 hs. SIMPOSIO ASTRAZENECA*

*12:30 – 13:30 hs. Intervalo Almuerzo*



# Jueves 12 de Mayo

## 13:30 – 14:35 hs. Módulo 2: Cáncer de Pulmón

13:30 – 13:35 hs. Presidente: Dra. Berta Roth, CEMIC, Buenos Aires

Coordinador: Dr. Aldo Quarneti,  
Hospital Pereira Rossell, Montevideo, Uruguay

### Disertantes:

13:35 – 13:45 hs. Dr. Pablo Andrada, Hospital Alemán, Buenos Aires

Abstract 98: Pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC: KEYNOTE-799

Abstract 99: Prospective Phase I/II Study of Radiation and Chemotherapy with Ipilimumab followed by Nivolumab for Patients with Stage III Unresectable NSCLC

13:45 – 13:55 hs. Dra. Andrea Pozo, Hospital Alemán, Buenos Aires

Abstract 100: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy (SABR) in advanced non-small cell lung cancer, progressing after first or second line chemotherapy (NIVORAD)

Abstract 101: Mature Outcomes of 61.2 Gy Concomitant Boost (CB) Thoracic Radiotherapy (TRT) in Limited Stage Small Cell Lung Cancer (LSCLC): CALGB 30610 (Alliance) / RTOG 0538

13:55 – 14:05 hs. Dr. Pablo Converso, Vidt Centro Médico, Buenos Aires

Abstract 102: A Phase II Trial of Primary Tumor SBRT Boost Prior to Concurrent Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer (LA-NSCLC)

Abstract 106: Prospective Evaluation of Stereotactic Body Radiotherapy and Immunotherapy for Mediastinal and Hilar Lymph Node Metastases

14:05 – 14:35 hs. Mesa de Discusión:

Coordinador: Dr. Aldo Quarneti (RT)

Panelistas: Dra. Berta Roth (RT), Dr. Pablo Andrada (RT), Dra. Andrea Pozo (RT),  
Dr. Pablo Converso (RT)

Dr. Felipe Couñago, **Oncología Radioterápica,**

Hospital Universitario Quirónsalud, Madrid, España

Dr. Claudio Martín, **Oncología Clínica,** Instituto Alexander Fleming, Bs. As..

# Jueves 12 de Mayo

## 14:35 – 15:50 hs. Módulo 3: Cáncer Genitourinario

14:35 – 14:40 hs. Presidente: Dra. Carmen Castro, Hospital Alemán, Buenos Aires

Coordinadora: Dra. Carolina Chacón, Instituto Alexander Fleming, B. A.

### Disertantes:

14:40 – 14:50 hs. Dr. Sergio Quiceno, Vidt Centro Médico, Buenos Aires

**Abstract 48: Primary Endpoint Analysis of a Randomized Phase III Trial of Hypofractionated versus Conventional Post-Prostatectomy Radiotherapy: NRG Oncology GU003**

**Abstract 49: Dose Escalated Radiotherapy Alone or in Combination with Short-Term Androgen Suppression for Intermediate Risk Prostate Cancer: Outcomes from the NRG Oncology/RTOG 0815 Randomized Trial**

14:50 – 15:00 hs. Dra. Beatriz Mazza, Centro de Radioterapia Gral. San Martín, Bs. As.

**Abstract 50: 10-Year Results of a Phase III Randomized Trial of High-Dose Radiotherapy and Risk-Adapted Androgen Deprivation in Localized Prostate Cancer**

**Abstract 53: Individual Patient Data Meta-Analysis of Randomized trials in Cancer of the Prostate (MARCAP) Consortium: Impact of Androgen Deprivation Therapy Use and Duration with Definitive Radiotherapy for Localized Prostate Cancer**

15:00 – 15:10 hs. Dr. Marcelo Andrade Irusta, CEMIC, Buenos Aires

**Abstract 55: Impact of High Dose Radiotherapy (HEAT) in Localized Prostate Cancer: An Individual Patient Data (IPD) Meta-Analysis of 15 Randomized Trials**

**Abstract 56: Elective nodal ultra hypofractionated radiation for prostate cancer: safety and efficacy from four prospective clinical trials**

15:10 – 15:20 hs. Dr. Juan Pablo Sade, Hospital Universitario Austral, Buenos Aires

**Abstract 51: Performance of a Genomic Classifier (GC) within a Phase 3 Randomized Trial of Dose Escalated Salvage Radiotherapy (SRT) after Radical Prostatectomy (RP)**

**Abstract 52: Validation of a 22-gene Genomic Classifier in the NRG Oncology/RTOG 9202, 9413 and 9902 Phase III Randomized Trials: a Biopsy-Based Individual Patient Meta-Analysis in High-Risk Prostate Cancer**

**15.20 – 15:50 hs. Mesa de Discusión:**

**Coordinadora:** Dra. Carolina Chacón (RT)

**Panelistas:** Dra. Carmen Castro (RT), Dr. Sergio Quiceno (RT), Dra. Beatriz Mazza (RT),  
Dr. Marcelo Andrade Irusta (RT), Dr. Juan Pablo Sade (Oncología Clínica)  
Dr. Felipe Couñago, **Oncología Radioterápica,**

Hospital Universitario Quirónsalud, Madrid, España

Dr. Gustavo Villoldo, **Urología,** Instituto Alexander Fleming, Buenos Aires

15:50 – 16:20 hs. Intervalo Café

# Jueves 12 de Mayo

## 16:20 – 17:35 hs. Módulo 4: Hematología Oncológica

16:20 – 16:25 hs. **Presidente:** Dr. Oscar Gómez Orrego, Consultorio Privado de Radiaciones Gral. San Martín, Buenos Aires

**Coordinador:** Dr. Juan José Galarraga, Centro de Oncología y Radioterapia, Mar del Plata, Buenos Aires

### Disertantes:

16:25 – 16:35 hs. **Dra. Ana Mabel Martínez, CEDITRIN, Buenos Aires**

**Abstract 78: PET-Based Quantification of Baseline Metabolic Tumor Burden Improves Risk Stratification in High-Risk Hodgkin Lymphoma: A Children's Oncology Group Study**

**Abstract 80: An international, multi-centre study of radiotherapy for bilateral indolent orbital adnexal lymphomas (IOAL)**

16:35 – 16:45 hs. **Dr. Ariel Gómez Palacios, Centro de Radioterapia Dean Funes, Córdoba**

**Abstract 81: The impact of surveillance imaging after curative intent radiotherapy for limited stage follicular lymphoma**

**Abstract 82: Radiotherapy bridging in patients with r/r high-grade lymphoma receiving CD19 CAR-T in the UK**

16:45 – 16:55 hs. **Dr. Luis Carvajal, Centro Médico Dean Funes, La Plata, Buenos Aires**

**Abstract 83: Predictors of Response to Very Low Dose Radiotherapy (4Gy) For Indolent B-Cell Lymphomas: Is 4Gy Also Suitable for Potentially Curable Patients?**

**Abstract 84: Clinical Outcomes of Post-transplant lymphoproliferative disease (PTLD): Role of radiation therapy in improvement of disease response**

16:55 – 17:05 hs. **Dra. Belén Nahir Raiden, Centro de Radioterapia Dean Funes, Córdoba**

**Abstract 85: Consolidative Radiotherapy Remains a Key Player in the Salvage Management of Hodgkin Lymphoma**

**Abstract 87: Radiation Therapy Can Be Safely Incorporated into Pre-transplant Treatment Regimens for Patients with Multiple Myeloma**

**17:05 – 17:35 hs. Mesa de Discusión:**

**Coordinador: Dr. Juan Galarraga (RT)**

**Panelistas: Dr. Oscar Gómez Orrego (RT), Ana Mabel Martínez (RT), Dr. Luis Carvajal (RT), Dr. Ariel Gómez Palacios (RT), Dr. Belén Nahir Raiden (RT), Dra. Astrid Pavlovsky, Onco-Hematología, Centro Médico FUNDALEU, Bs. As.**

# Viernes 13 de Mayo

**08:30 – 12:30 hs. Acreditación**

**09:00 – 10:15 Módulo 5: Sistema Nervioso Central**

**09:00 – 09:05 hs. Presidente: Dr. Lucas Causa,**  
Centro de Radioterapia Dean Funes, Córdoba

**Coordinadores: Dr. Ignacio Sisamón, Centro de Oncología y Radioterapia, Mar del Plata**  
**Dr. José Máximo Barros, Hospital Universitario Austral, Buenos Aires**

**Disertantes:**

**09:05 – 09:15 hs. Dra. Silvia Hansing, Centro Oncológico Integral “COI”, Neuquén**

**Abstract 10: Phase I Dose Escalation Trial of Hypofractionated Radiosurgery for Large Intact or Resected Brain Metastases**

**Abstract 9: Long-Term Outcomes of a Prospective Clinical Trial of Proton Craniospinal Irradiation for Leptomeningeal Metastasis**

**09:15 – 09:25 hs. Dr. Gastón Lemoine, Instituto de Radiaciones, Salta**

**Abstract 8: A randomized trial of short-course versus conventional radiotherapy with concomitant and adjuvant temozolomide in patients 18 to 70 years of age with glioblastoma**

**Abstract 12: Dose-Escalated Accelerated Hypofractionation for Patients with a Newly Diagnosed Glioblastoma: A Pooled International Study**

**09:25 – 09:35 hs. Dr. Diego Gronovich, Vidt Centro Médico, Buenos Aires**

**Abstract 15: Higher Radiation Doses to Motor Regions Predict Decline in Fine Motor Skills After Brain RT: NTCP Analysis of a Prospective Trial**

**Abstract 16: Fractionated Proton Beam Radiation Therapy and Hearing Preservation for Vestibular Schwannoma: Preliminary Analysis of a Prospective Phase 2 Clinical Trial**

**09:35 – 09:45 hs. Dr. Gerardo Gabriel Heinrich, Centro de RT Río Cuarto, Córdoba**

**Abstract 13: 18F-DOPA-PET-Guided Re-Irradiation for Recurrent High-Grade Glioma: Initial Results of a Phase II Trial**

**Abstract 17: Frameless MLC-Based Radiosurgical Thalamotomies on the Modern Linear Accelerator Platform — Prospective Phase I/II Clinical Trial Results**

**09:45 – 10:15 hs. Mesa de Discusión:**

**Coordinadores: Dr. Ignacio Sisamón (RT), Dr. José Máximo Barros (RT)**

**Panelistas: Dr. Lucas Causa (RT), Dra. Silvia Hansing (RT), Dr. Gastón Lemoine (RT),**

**Dr. Diego Gronovich (RT), Dr. Gerardo Gabriel Heinrich (RT)**

**Dr. Jorge Mandolesi, Neurocirugía, Instituto FLENI, Buenos Aires**

**Dra. Carmen Rubio (RT), Hospital Universitario HM Sanchinarro, Madrid, España**

**Dr. Alejandro Muggeri, Oncología, Instituto FLENI, Buenos Aires**

**Dr. Mauricio Luongo (RT), Clínica COR, Montevideo, Uruguay**

**Dr. Fernando Saguier, Neuroradiología, Hospital Universitario Austral, Bs. As.**

# Viernes 13 de Mayo

## 10:15 – 11:20 hs. *Módulo 6: Cáncer de Mama*

10:15 – 10:20 hs. **Presidente:** Dra. Patricia Bruno, CEPROR, Villa María, Córdoba  
**Coordinadora:** Dra. Verónica Vázquez Balcarce, CEDITRA, Bs. As.

### Disertantes:

10:20 – 10:25 hs. **Dra. Luisa Rafailovici, Vidt Centro Médico, Buenos Aires (A Confirmar)**

**Abstract 1: Elective internal mammary node irradiation in women with node-positive breast cancer: Results of a randomized, phase 3 trial.**

10:25 – 10:35 hs. **Dra. Vanesa Krakobsky, Mevaterapia Oncología Radiante, Bs. As.**

**Abstract 2: MC1635: Randomized Phase III Trial Of Hypofractionated Radiotherapy To The Whole Breast After Breast Conserving Surgery**

**Abstract 3: OPAR: A Multicenter Phase II Randomized Trial of Fractionation Schedules for Once-a-Day Accelerated Partial Breast Irradiation (APBI)**

10:35 – 10:45 hs. **Dr. Ernesto Korbenfeld, Hospital Británico, Buenos Aires**

**Abstract 5: Local therapy outcomes and toxicity from the ATEMPT trial (TBCRC 033), A Phase II randomized trial of adjuvant T-DM1 vs TH in women with stage I HER2 positive breast cancer**

**Abstract 6: One-Year Toxicity Report of the RADIOPARP Phase I Trial Evaluating Olaparib With Radiotherapy for Triple Negative Breast Cancer**

10:45 – 10:50 hs. **Dra. Ana Díaz Gavela,  
Hospital Universitario Quirónsalud, Madrid, España**

**Abstract 7: Evaluation of Cardiotoxicity in HER-2 Positive Breast Cancer Patients Treated with Radiation Therapy and Trastuzumab**

### 10:50 – 11:20 hs. Mesa de Discusión:

**Coordinador:** Dra. Verónica Vázquez Balcarce (RT)

**Panelistas:** Dra. Patricia Bruno (RT), Dra. Luisa Rafailovici (RT), Vanesa Krakobsky (RT), Dr. Ernesto Korbenfeld (**Oncología Clínica**), Dra. Ana Díaz Gavela (RT)  
Dra. Cristina Noblía, **Mastología**, Sanatorio Otamendi, Buenos Aires

## 11:20 – 11:50 hs. *Intervalo Café*

# Viernes 13 de Mayo

## 11:50 – 13:05 hs. Módulo 7: Cáncer Gastrointestinal

11:50 – 11:55 hs. **Presidente:** Dr. Carlos Donoso,  
Centro de Radioterapia CITO, San Isidro, Buenos Aires  
**Coordinadora:** A Confirmar

### Disertantes:

11:55 – 12:05 hs. **Dra. Mabel Sardi, Mevaterapia Oncología Radiante, Buenos Aires**

**Abstract 38: Long-term Patient-Reported Quality of Life and Functional Outcomes After Chemoradiation Using Intensity Modulated Radiotherapy for Anal Cancer**

**Abstract 39: Multi-Institutional Comparison of SC-TNT and LC-TNT for Rectal Cancer Non-Operative Management**

12:05 – 12:15 hs. **Dra. Clara Rojas Castillo, Vidt Centro Médico, Bs. As.**

**Abstract 40: High SMAD4 Expression is Associated with Better Clinical Outcomes in Patients with Resectable Pancreatic Cancer: An analysis of NRG Oncology/RTOG 9704**

**Abstract 42:  $\beta$ -catenin is independently associated with outcome in pancreatic cancer: An analysis of NRG Oncology/RTOG 9704**

12:15 – 12:25 hs. **Dr. José Capraro Fuentes,**  
Centro de Radioterapia CITO, San Isidro, Buenos Aires

**Abstract 41: Exclusive chemoradiotherapy with or without radiation dose escalation in esophageal cancer: multicentre phase 2/3 randomized trial CONCORDE (PRODIGE-26)**

**Abstract 44: Increased Esophageal Perforation after Combination of Anti-PD-1 Immunotherapy with Radiotherapy for Esophageal Carcinoma**

12:25 – 12:35 hs. **Dr. Augusto Alva, Mevaterapia Oncología Radiante, Buenos Aires**

**Abstract 45: Prospective Validation of the Magnetic Resonance Tumor Regression Grade (MR-TRG) and Correlation with Pathologic Endpoints Score In NRG Oncology GI002**

**Abstract 46: The Feasibility of Quality Assurance in the TOPGEAR International Phase III Clinical Trial of Neoadjuvant Chemoradiotherapy for Gastric Cancer (An Intergroup Trial of the AGITG/TROG/EORTC/CCTG)**

**12:35 – 13:05 hs. Mesa de Discusión:**

**Coordinadora:** A Confirmar

**Panelistas:** Dra. Clara Rojas Castillo (RT), Dra. Mabel Sardi (RT), Dr. Carlos Donoso (RT),  
Dra. José Capraro Fuentes (RT), Dr. Augusto Alva (RT),  
Dr. Eduardo Huertas, **Cirugía**, Instituto Alexander Fleming, Buenos Aires  
Dr. Mario Barugel, **Oncología Clínica**, Ex Médico Hospital Udaondo, Bs. As.  
Dra. Lorena Savluk, **Diagnostico por Imágenes**, Hospital Italiano, Bs. As.

*Viernes 13 de Mayo*

*13:05 – 13:35 hs. Simposio VARIAN*

*13:35 – 14:35 hs. Intervalo: Lunch SATRO*



# Viernes 13 de Mayo

## 14:35 – 15:45 hs. Módulo 8: Cáncer Ginecológico

14:35 – 14:40 hs. **Presidente:** Dr. Mauro Mattio, Vidt Centro Médico, Buenos Aires  
**Coordinador:** Dr. Gustavo Sarria,  
Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, Perú

### Disertantes:

14:40 – 14:50 hs. Dr. Gastón Lemoine, Instituto de Radiaciones, Salta

**Abstract 59: Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus (SPARTACUS): A Multicenter Prospective Trial Evaluating Acute Toxicities and Patient Reported Outcomes**

**Abstract 60: Phase I Dose Escalation Clinical Trial of Stereotactic Body Radiation Therapy (SBRT) for Limited Locoregional Recurrences of Ovarian Cancer**

14:50 – 15:00 hs. Dra. Luciana Brun, Centro de Radioterapia Dean Funes, Córdoba

**Abstract 62: Prophylactic Extended-Field Irradiation vs. Pelvic Irradiation in Cervical Cancer Patients With 2018 FIGO IIIC1 Diseases**

**Abstract 64: The Role of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic and Oligoprogressive Gynecologic Malignancies: A Multi-Institutional Pooled Analysis**

15:00 – 15:15 hs. Dr. Andrés Quintero, Terapia Radiante, La Plata, Buenos Aires

**Abstract 58: Weekly cisplatin versus triweekly docetaxel plus cisplatin with concurrent chemoradiation in post-operative treatment for cervical cancer with high-risk pathological factors: A randomized controlled phase III trial from a single institution**

**Abstract 61: Chemoradiation with or without Metformin in Locally Advanced Cervical Cancer: Phase II Randomized Trial**

**Abstract 65: Prognostic Impact of Mismatch Repair Deficiency in High- and Low-Intermediate Risk, Early-Stage Endometrial Cancer Following Vaginal Brachytherapy**

### 15:15 – 15:45 hs. Mesa de Discusión:

**Coordinador:** Dr. Gustavo Sarria (RT)

**Panelistas:** Dr. Mauro Mattio (RT), Dr. Gastón Lemoine (RT), Luciana Brun (RT),  
Dr. Andrés Quintero (RT)

Dr. José Saadi, **Cirugía Oncológica**, Hospital Italiano, Buenos Aires

Dra. Liliana Zamora, **Oncología Clínica**, Hospital Italiano, Buenos Aires

## 15:45 – 16:00 hs. Intervalo Café

# Viernes 13 de Mayo

**16:00 – 17:10 hs. Módulo 9: Cuidados Paliativos**

**Organizado por el Capítulo de Jóvenes Radioterapeutas de SATRO**

**16:00 – 16:05 hs. Presidente: Dr. Javier Otero, Hospital Universitario Austral, Bs. As.**

**Coordinadora: Dra. Marina Peña Huertas,  
Hospital Universitario Quirónsalud, Madrid, España**

**Disertantes:**

**16:05 – 16:10 hs. Dr. Matías Zapata, Hospital Universitario Austral, Buenos Aires**

**Abstract 108: Population Based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR) for up to 5 Oligometastases: Preliminary Results of the SABR-5 trial**

**16:10 – 16:20 hs. Dra. Taire Brito, Vidt Centro Médico, Buenos Aires**

**Abstract 111: Assessment of Treatment Response and Re-bleeding after Palliative Radiation Therapy for Bleeding Gastric Cancer: A Longitudinal Multicenter Prospective Observational Study**

**Abstract 109: Prospective characterization of circulating tumor cell kinetics in patients with oligometastatic disease receiving definitive radiation therapy**

**16:20 – 16:30 hs. Dra. Carolina Arzuaga Barreneche, Instituto Ángel Roffo, Bs. As.**

**Abstract 112: Impact of Volumetric Burden of Metastatic Lesions on Outcomes in Extracranial Oligometastatic Patients: A Multi-Institutional Study**

**Abstract 117: Predictors of Skeletal Related Events in Patients Treated with Surgical Stabilization for Bone Metastases With or Without Radiotherapy**

**16:30 – 16:40 hs. Dr. Kenzo Higa, Mevaterapia Oncología Radiante, Buenos Aires**

**Abstract 113: Phase II clinical trial of separation surgery followed by stereotactic body radiotherapy for metastatic epidural spinal cord compression**

**Abstract 114: Development and internal validation of an RPA-based model predictive of pain flare incidence after spine SBRT**

**16:40 – 17:10 hs. Mesa de Discusión:**

**Coordinadora: Dra. Marina Peña Huertas, Radioncología,  
Hospital Universitario Quirónsalud, Madrid, España**

**Panelistas: Dr. Javier Otero (RT), Dr. Matías Zapata (RT), Dra. Taire Brito (RT),  
Dra. Carolina Arzuaga Barreneche (RT), Dr. Kenzo Higa (RT)  
Dra. Carolina Passarella, **Oncología Clínica**, Hospital Universitario Austral, BA  
Dra. Mariana Fiorani, **Médica Paliativista**, Universidad Favaloro, Buenos Aires**

**17:10 – 17:20 hs. Acto de Cierre VI Best of ASTRO**



# Sociedad Argentina de Terapia Radiante Oncológica



SCIENCE OF TODAY  
HOPE FOR TOMORROW

## Argentina